Clinical Trials Logo

Obstetric Labor, Premature clinical trials

View clinical trials related to Obstetric Labor, Premature.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT05612984 Withdrawn - Preterm Labor Clinical Trials

Calcium Aspirin Multiple Micronutrients (CAMMS) to Reduce Preterm Birth

CAMMS
Start date: April 1, 2024
Phase: Phase 3
Study type: Interventional

This trial will evaluate the impact of an integrated intervention of daily maternal calcium, aspirin, and multiple micronutrients (CAMMS) compared to iron-folic acid (IFA) during pregnancy on preterm birth and other adverse birth outcomes. Both interventions will be delivered through existing antenatal service platforms using context-specific strategies informed by formative research incorporating human-centered design processes to achieve high acceptability and high adherence, in three low-income countries with diverse contexts: Burkina Faso, Pakistan, and Zimbabwe.

NCT ID: NCT04301388 Withdrawn - Clinical trials for Preterm Delivery Within 7 Day After Admission

Management of Threatened Preterm Labor by Cervical Length-based Approach or Conventional Approach

Start date: January 22, 2020
Phase: N/A
Study type: Interventional

To compare the effectiveness of treatment of threatened preterm labor between transvaginal cervical length-based approach and conventional approach (Per vaginal examination)

NCT ID: NCT03517696 Withdrawn - Early Labor Clinical Trials

Membrane Sweeping in Early Labor and Delivery Outcomes

Start date: May 20, 2018
Phase: N/A
Study type: Interventional

Membrane sweeping is a routine procedure in obstetrics in term patients. It has been shown to be effective in decreasing post term gestation and in increasing rate of spontaneous vaginal delivery when used in setting of induction of labor in nulliparous patients. The goal of this study is to determine if membranes sweeping in early labor is effective in improving delivery outcomes including decreasing rate of cesarean section.

NCT ID: NCT03122704 Withdrawn - Preterm Labor Clinical Trials

Group B Streptococcus (GBS) Infection and in Preterm Labor Women Conceived Through IVF

Start date: October 2015
Phase: N/A
Study type: Interventional

This is a cross - sectional study to determine the prevalence of GBS infection and associated factors in preterm labor women conceived through ART. 221 subjects will be involved.

NCT ID: NCT03077633 Withdrawn - Preterm Birth Clinical Trials

Cerclage for Twins With Short Cervix

Start date: October 1, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

A prospective randomized control trial that will compare cervical cerclage plus vaginal progesterone to vaginal progesterone along in twin pregnancies complicate by a short cervix (</= 15.0mm) between 16w0d to 25w6d.

NCT ID: NCT02849301 Withdrawn - Preterm Birth Clinical Trials

Cervical Pessary in Women With Arrested Preterm Labor and Short Cervix

PWK
Start date: July 2016
Phase: Phase 3
Study type: Interventional

Preterm birth (PTB), defined as birth between 20 and 36 6/7 weeks, is responsible for the majority of the neonatal morbidity and mortality in the United States, and 35% of all U.S. healthcare spending on infants. Globally, about 28% of the 4 million annual neonatal deaths are directly attributable to PTB. Preterm labor (PTL) is the final pathway for about 50% of all PTB. Tocolytic agents are drugs that can slow or stop labor contractions in the attempt to delay births preceded by PTL. Primary tocolysis is defined as tocolysis given on initial presentation of women with PTL. In most of these women, PTL stops, but as their risk of PTB remains high, some have advocated use of maintenance tocolysis, i.e. tocolysis after arrested PTL. So far, no maintenance tocolytic agent has been shown to be beneficial in preventing PTB. The aim of this study is to evaluate the efficacy of maintenance tocolysis with Arabin pessary compared to standard care in singleton gestations with arrested PTL and with short transvaginal ultrasound (TVU) cervical length (CL) <25mm

NCT ID: NCT02569216 Withdrawn - Premature Birth Clinical Trials

Electrical Inhibition (EI): A Preliminary Study To Inhibit Preterm Labor And Preterm Birth

EI
Start date: February 9, 2016
Phase: Phase 1
Study type: Interventional

An electrical-inhibition (EI) uterine pacemaker device similar to an electrical heart pacemaker delivers a weak electrical current to the human uterus during active preterm labor to rapidly and safely inhibit the unwanted premature uterine contractions and possibly a preterm birth.

NCT ID: NCT02351310 Withdrawn - Premature Birth Clinical Trials

Effectiveness of ACS in Extreme Preemies

Start date: November 2015
Phase: Phase 3
Study type: Interventional

This is a randomized prospective clinical study that will evaluate the effects of antenatal corticosteroid administration (ACS) vs. placebo in singleton pregnancies who are threatening to deliver prematurely between 22 0/7 and 23 6/7 weeks on admission with the goal of improving composite neonatal mortality and morbidity.

NCT ID: NCT01869361 Withdrawn - Preterm Labor Clinical Trials

Indomethacin for Tocolysis of Preterm Labor

Start date: August 1, 2020
Phase: Early Phase 1
Study type: Interventional

Indomethacin for tocolysis for 48 hours vs placebo

NCT ID: NCT01406197 Withdrawn - Preterm Labor Clinical Trials

Uterine Electrical Activity Before and After Progesterone Treatment for Preterm Labor

Start date: July 2011
Phase: N/A
Study type: Interventional

This study will examine the effects of various formulations of progesterone on uterine electromyographic (EMG) activity in pregnant patients in premature labor to determine if progesterone will suppress uterine electrical activity and which formulation may be best for inhibition of uterine activity. Patients will be monitored prior to treatment and following treatment (every 2 to 4 hours) with one of three different formulations of progesterone for up to two days. Patients will continue to be observed until they deliver. Comparisons will be for uterine EMG activity from before treatment to that following treatments at 2, 4, 8, 12 24 and 48 hours and times of delivery after treatments (hours or days following treatments). Comparisons between mean values for EMG activity between the various treatments at the various times will also be made.